{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:19:10Z","timestamp":1785381550613,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05595-4","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T13:12:52Z","timestamp":1743858772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacotherapy for overactive bladder syndrome and the risk of incident dementia"],"prefix":"10.1007","volume":"43","author":[{"given":"David","family":"Sheyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhimanyu","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Emi","family":"Bretschneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adonis","family":"Hijaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"issue":"8","key":"5595_CR1","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.3390\/jcm12082859","volume":"12","author":"M Przydacz","year":"2023","unstructured":"Przydacz M, Gasowski J, Grodzicki T, Chlosta P (2023) Lower urinary tract symptoms and overactive bladder in a large cohort of older Poles-A representative Tele-Survey. J Clin Med 12(8):2859. https:\/\/doi.org\/10.3390\/jcm12082859PMID: 37109196; PMCID: PMC10142045","journal-title":"J Clin Med"},{"issue":"5","key":"5595_CR2","doi-asserted-by":"publisher","first-page":"e2315074","DOI":"10.1001\/jamanetworkopen.2023.15074","volume":"6","author":"D Luchristt","year":"2023","unstructured":"Luchristt D, Bretschneider CE, Kenton K, Simon M, Brown O (2023) Inequities in filled overactive bladder medication prescriptions in the US. JAMA Netw Open 6(5):e2315074. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.15074","journal-title":"JAMA Netw Open"},{"key":"5595_CR3","unstructured":"LiverTox Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jul 7, 2017. Anticholinergic Agents"},{"issue":"8","key":"5595_CR4","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","volume":"179","author":"CAC Coupland","year":"2019","unstructured":"Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J (2019) Anticholinergic drug exposure and the risk of dementia: A nested Case-Control study. JAMA Intern Med 179(8):1084\u20131093","journal-title":"JAMA Intern Med"},{"key":"5595_CR5","doi-asserted-by":"crossref","unstructured":": PMC6593623. 10.1001\/jamainternmed.2019.0677. PMID: 31233095, PMCID, Richardson K, Fox C, Maidment I et al (2018) Anticholinergic drugs and risk of dementia: case-control study. BMJ.;361:k1315","DOI":"10.1136\/bmj.k1315"},{"issue":"3","key":"5595_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","volume":"175","author":"SL Gray","year":"2015","unstructured":"Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, Yu O, Crane PK, Larson EB (2015) Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 175(3):401\u2013407","journal-title":"JAMA Intern Med"},{"key":"5595_CR7","doi-asserted-by":"crossref","unstructured":"Nina T, Pieper CM, Grossi W-Y, Chan, Yoon K, Loke GM, Savva C, Haroulis N, Steel C, Fox ID, Maidment, Antony J, Arthur, Phyo K, Myint, Toby O, Smith L, Robinson, Fiona E, Matthews (November 2020) Carol Brayne, Kathryn Richardson, anticholinergic drugs and incident dementia, mild cognitive impairment and cognitive decline: a meta-analysis. Age Ageing 49(6):939\u2013947","DOI":"10.1093\/ageing\/afaa090"},{"key":"5595_CR8","doi-asserted-by":"publisher","first-page":"e12290","DOI":"10.1002\/trc2.12290","volume":"8","author":"J Mur","year":"2022","unstructured":"Mur J, Russ TC, Cox SR, Marioni RE, Muniz-Terrera G (2022) Association between anticholinergic burden and dementia in UK biobank. Alzheimer\u2019s Dement 8:e12290. https:\/\/doi.org\/10.1002\/trc2.12290","journal-title":"Alzheimer\u2019s Dement"},{"issue":"4","key":"5595_CR9","doi-asserted-by":"publisher","first-page":"F859","DOI":"10.1152\/ajprenal.00215.2017","volume":"313","author":"K Okeke","year":"2017","unstructured":"Okeke K, Gravas S, Michel MC (2017) Do \u03b23-adrenoceptor agonists cause urinary bladder smooth muscle relaxation by inhibiting acetylcholine release? Am J Physiol Ren Physiol 313(4):F859\u2013F861. https:\/\/doi.org\/10.1152\/ajprenal.00215.2017Epub 2017 May 17. PMID: 28515177","journal-title":"Am J Physiol Ren Physiol"},{"issue":"2","key":"5595_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2125.2011.03961.x","volume":"72","author":"E Callegari","year":"2011","unstructured":"Callegari E, Malhotra B, Bungay PJ et al (2011) A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 72(2):235\u2013246","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"5595_CR11","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1016\/j.jamda.2021.08.011","volume":"22","author":"D Bishara","year":"2021","unstructured":"Bishara D, Perera G, Harwood D et al (2021) Centrally acting anticholinergic drugs used for urinary conditions associated with worse outcomes in dementia. J Am Med Dir Assoc 22(12):2547\u20132552","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"5595_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/iju.12288","volume":"21","author":"R Sakakibara","year":"2014","unstructured":"Sakakibara R, Panicker J, Fowler CJ, Tateno F, Kishi M, Tsuyusaki Y, Yamanishi T, Uchiyama T, Yamamoto T, Yano M (2014) Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly. Int J Urol 21(1):33\u201338. https:\/\/doi.org\/10.1111\/iju.12288Epub 2013 Sep 30. PMID: 24118122","journal-title":"Int J Urol"},{"key":"5595_CR13","first-page":"1","volume":"2","author":"U Topaloglu","year":"2018","unstructured":"Topaloglu U, Palchuk MB (2018) Using a federated network of real-world data to optimize clinical trials operations. JCO Clin Cancer Inf 2:1\u201310","journal-title":"JCO Clin Cancer Inf"},{"issue":"7624","key":"5595_CR14","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, STROBE Initiative (2007) Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335(7624):806\u2013808. https:\/\/doi.org\/10.1136\/bmj.39335.541782.ADPMID: 17947786; PMCID: PMC2034723","journal-title":"BMJ"},{"key":"5595_CR15","doi-asserted-by":"publisher","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity measures for use with administrative data. Med Care.;36(1):8\u201327. https:\/\/doi.org\/10.1097\/00005650-199801000-00004. PMID: 9431328","DOI":"10.1097\/00005650-199801000-00004"},{"issue":"2","key":"5595_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00228-020-02994-x","volume":"77","author":"A Lisibach","year":"2021","unstructured":"Lisibach A, Benelli V, Ceppi MG, Waldner-Knogler K, Csajka C, Lutters M (2021) Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review. Eur J Clin Pharmacol 77(2):147\u2013162. https:\/\/doi.org\/10.1007\/s00228-020-02994-xEpub 2020 Oct 3. PMID: 33011824; PMCID: PMC7803697","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"5595_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/jpm12020207","volume":"12","author":"H Ramos","year":"2022","unstructured":"Ramos H, Moreno L, P\u00e9rez-Tur J, Ch\u00e1fer-Peric\u00e1s C, Garc\u00eda-Lluch G, Pardo J (2022) CRIDECO anticholinergic load scale: an updated anticholinergic burden scale. Comparison with the ACB scale.in Spanish individuals with subjective memory complaints. J Pers Med 12(2):207. https:\/\/doi.org\/10.3390\/jpm12020207PMID: 35207695; PMCID: PMC8876932","journal-title":"J Pers Med"},{"issue":"2","key":"5595_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2125.2011.03961.x","volume":"72","author":"E Callegari","year":"2011","unstructured":"Callegari E, Malhotra B, Bungay PJ, Webster R, Fenner KS, Kempshall S, LaPerle JL, Michel MC, Kay GG (2011) A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 72(2):235\u2013246","journal-title":"Br J Clin Pharmacol"},{"key":"5595_CR19","doi-asserted-by":"crossref","unstructured":"Xie J, Liu C (2005) Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat Med.;24(20):3089\u2013\u2009110. doi: 10.1002\/sim.2174. Erratum in: Stat Med. 2007;26(10):2276. PMID: 16189810","DOI":"10.1002\/sim.2174"},{"issue":"28","key":"5595_CR20","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA (2015) Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34(28):3661\u20133679. https:\/\/doi.org\/10.1002\/sim.6607Epub 2015 Aug 3. PMID: 26238958; PMCID: PMC4626409","journal-title":"Stat Med"},{"issue":"1","key":"5595_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/bju.15040","volume":"126","author":"B Welk","year":"2020","unstructured":"Welk B, McArthur E (2020) Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study. BJU Int 126(1):183\u2013190. https:\/\/doi.org\/10.1111\/bju.15040Epub 2020 Mar 19. PMID: 32167223","journal-title":"BJU Int"},{"issue":"11","key":"5595_CR22","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1080\/14740338.2017.1376646","volume":"16","author":"G Araklitis","year":"2017","unstructured":"Araklitis G, Cardozo L (2017) Safety issues associated with using medication to treat overactive bladder. Expert Opin Drug Saf 16(11):1273\u20131280 Epub 2017 Sep 10. PMID: 28889761","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"5595_CR23","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1097\/JU.0000000000002882","volume":"208","author":"T Kawada","year":"2022","unstructured":"Kawada T (2022) Dementia associated with anticholinergic drugs used for overactive bladder: A Nested-Case control study using the French National Medical-Administrative database. Letter J Urol 208(4):792\u2013793. https:\/\/doi.org\/10.1097\/JU.0000000000002882Epub 2022 Aug 5. PMID: 35930792","journal-title":"Letter J Urol"},{"key":"5595_CR24","doi-asserted-by":"crossref","unstructured":"Park JS, Choi SB, Jang WS, Kim J, Ham WS (2024) Risks of Dementia After Treatment with an Anticholinergic, Beta-3 Agonist, or Combination of Both for an Overactive Bladder: A Korean National Cohort Study. Eur Urol Focus. Feb 21:S2405-4569(24)00019\u2013\u20091. doi: 10.1016\/j.euf.2024.02.002. Epub ahead of print. PMID: 38388215","DOI":"10.1016\/j.euf.2024.02.002"},{"key":"5595_CR25","doi-asserted-by":"publisher","first-page":"1376535","DOI":"10.3389\/fphar.2024.1376535","volume":"15","author":"J Wang","year":"2024","unstructured":"Wang J, Zhang A, Ye M, Zhang C (2024) Examining the safety of Mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database. Front Pharmacol 15:1376535. https:\/\/doi.org\/10.3389\/fphar.2024.1376535PMID: 38562462; PMCID: PMC10982368","journal-title":"Front Pharmacol"},{"issue":"2","key":"5595_CR26","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/jcb.26321","volume":"119","author":"H Li","year":"2018","unstructured":"Li H, Yang S, Wu J, Ji L, Zhu L, Cao L, Huang J, Jiang Q, Wei J, Liu M, Mao K, Wei N, Xie W, Yang Z (2018) cAMP\/PKA signaling pathway contributes to neuronal apoptosis via regulating IDE expression in a mixed model of type 2 diabetes and Alzheimer\u2019s disease. J Cell Biochem 119(2):1616\u20131626. https:\/\/doi.org\/10.1002\/jcb.26321Epub 2017 Sep 28. PMID: 28771808","journal-title":"J Cell Biochem"},{"key":"5595_CR27","doi-asserted-by":"publisher","unstructured":"Lonze BE, Ginty DD (2002) Function and regulation of CREB family transcription factors in the nervous system. Neuron.;35(4):605\u2013\u200923. https:\/\/doi.org\/10.1016\/s0896-6273(02)00828-0. PMID: 12194863","DOI":"10.1016\/s0896-6273(02)00828-0"},{"issue":"3","key":"5595_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s13318-016-0350-5","volume":"42","author":"M Groen-Wijnberg","year":"2017","unstructured":"Groen-Wijnberg M, van Dijk J, Krauwinkel W, Kerbusch V, Meijer J, Tretter R, Zhang W, van Gelderen M (2017) Pharmacokinetic interactions between mirabegron and Metformin, Warfarin, Digoxin or combined oral contraceptives. Eur J Drug Metab Pharmacokinet 42(3):417\u2013429","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"5","key":"5595_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/2042098616658399","volume":"7","author":"SL Gray","year":"2016","unstructured":"Gray SL, Hanlon JT (2016) Anticholinergic medication use and dementia: latest evidence and clinical implications. Ther Adv Drug Saf 7(5):217\u2013224 doi: 10.1177\/2042098616658399. Epub 2016 Jul 18. PMID: 27695623; PMCID: PMC5014048","journal-title":"Ther Adv Drug Saf"},{"key":"5595_CR30","doi-asserted-by":"publisher","unstructured":"Matta R, Gomes T, Juurlink D, Jarvi K, Herschorn S, Nam RK (2022) Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study. Eur Urol Focus.;8(5):1433\u20131440. https:\/\/doi.org\/10.1016\/j.euf.2021.10.009. Epub 2021 Nov 4. PMID: 34742663","DOI":"10.1016\/j.euf.2021.10.009"},{"key":"5595_CR31","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1038\/s41598-021-84229-2","volume":"11","author":"T Harnod","year":"2021","unstructured":"Harnod T, Yang YC, Chiu LT et al (2021) Use of bladder antimuscarinics is associated with an increased risk of dementia: a retrospective population-based case\u2013control study. Sci Rep 11:4827","journal-title":"Sci Rep"},{"issue":"4","key":"5595_CR32","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1097\/JU.0000000000002804","volume":"208","author":"MF Malcher","year":"2022","unstructured":"Malcher MF, Droupy S, Berr C, Ziad A, Huguet H, Faillie JL et al (2022) Dementia associated with anticholinergic drugs used for overactive bladder: A nested Case-Control study using the French National Medical-Administrative database. J Urol 208(4):863\u2013871","journal-title":"J Urol"},{"issue":"5","key":"5595_CR33","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s13524-017-0598-7","volume":"54","author":"E Fishman","year":"2017","unstructured":"Fishman E (2017) Risk of developing dementia at older ages in the united States. Demography 54(5):1897\u20131919. https:\/\/doi.org\/10.1007\/s13524-017-0598-7PMID: 28776169; PMCID: PMC5624986","journal-title":"Demography"},{"key":"5595_CR34","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S1474-4422(07)70291-0","volume":"6","author":"S Seshadri","year":"2007","unstructured":"Seshadri S, Wolf PA (2007) Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham study. Lancet Neurol 6:1106\u20131114. https:\/\/doi.org\/10.1016\/S1474-4422(07)70291-0","journal-title":"Lancet Neurol"},{"key":"5595_CR35","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1212\/WNL.49.6.1498","volume":"49","author":"S Seshadri","year":"1997","unstructured":"Seshadri S, Wolf PA, Beiser A, Au R, McNulty K, White R, D\u2019Agostino RB (1997) Lifetime risk of dementia and Alzheimer\u2019s disease: the impact of mortality on risk estimates in the Framingham study. Neurology 49:1498\u20131504. https:\/\/doi.org\/10.1212\/WNL.49.6.1498","journal-title":"Neurology"},{"issue":"9","key":"5595_CR36","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s40266-023-01050-4","volume":"40","author":"HU Michael","year":"2023","unstructured":"Michael HU, Enechukwu O, Brouillette MJ, Tamblyn R, Fellows LK, Mayo NE (2023) The prognostic utility of anticholinergic burden scales: an integrative review and gap analysis. Drugs Aging 40(9):763\u2013783","journal-title":"Drugs Aging"},{"issue":"2","key":"5595_CR37","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.4081\/ni.2012.e13","volume":"4","author":"R Sakakibara","year":"2012","unstructured":"Sakakibara R, Panicker J, Fowler CJ, Tateno F, Kishi M, Tsuyuzaki Y, Ogawa E, Uchiyama T, Yamamoto T (2012) Vascular incontinence: incontinence in the elderly due to ischemic white matter changes. Neurol Int 4(2):e13. https:\/\/doi.org\/10.4081\/ni.2012.e13Epub 2012 Sep 6. PMID: 23139851; PMCID: PMC3490472","journal-title":"Neurol Int"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05595-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05595-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05595-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:54:11Z","timestamp":1767966851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05595-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5595"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05595-4","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DS: Research Support: Medtronic, Inc; Thermo Fisher, Axonics Inc, Consulting Fee: Caldera Medical, Stock: CollaMedix; AH: Research Support: BlueWind; Stock: CollaMedix; CEB: Consulting Fee: Avation Medical, Boston Scientific.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"212"}}